Track topics on Twitter Track topics that are important to you
Athersys, Inc. and HEALIOS K.K. announced today their intent to significantly expand their existing development and commercialization collaboration. As part of this expansion, Healios is making an app...
In return for offering Healios KK the chance to market its therapies in Japan, Athersys gets milestone payments up to US$360mln
UK-based digital therapy group Healios has raised £2.2 million in its latest funding round.
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties Discussions extende...
CLEVELAND and TOKYO, May 01, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) and HEALIOS K.K. (“Healios”) (TSE Mothers Code:4593) have agreed to extend the period from April 30, 2018 to...
Company Name: Healios K.K. (formerly known as Retina Institute Japan K.K.)Location: Tokyo, JapanPresident and CEO: Hardy TS Kagimoto, M.D.Founded: February 24, 2011Stock Market: ...
We have published hundreds of Healios K.K. news stories on BioPortfolio along with dozens of Healios K.K. Clinical Trials and PubMed Articles about Healios K.K. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Healios K.K. Companies in our database. You can also find out about relevant Healios K.K. Drugs and Medications on this site too.